hwf2u0

Property	Value
?:abstract	Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020 The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020 All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded Therefore, the study prospectively recorded all the COVID-19 ILI events Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2 Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0 9% [95% confidence interval (CI): 0 3–2 4], a hospitalization rate of 100% and a mortality rate of 77 8% Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1 5% (95% CI: 0 5–3 1), with 100% hospitalization and 64% mortality The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated (p = 0 009, p < 0 0001, p < 0 0001) Overall COVID-19 prevalence was 1 2% for vaccinated (six of 482 cases, all confirmed) and 1 7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0 52 The difference remained non-significant, considering confirmed COVID-19 only (p = 0 33) Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases Influenza vaccination does not protect from SARS-CoV-2 infection
is ?:annotates of	<https://research.tib.eu/covid-19/entity/36hwf2u0_hasAnnotation_C0009566> <https://research.tib.eu/covid-19/entity/36hwf2u0_hasAnnotation_C0392171> <https://research.tib.eu/covid-19/entity/36hwf2u0_hasAnnotation_C0877373> <https://research.tib.eu/covid-19/entity/36hwf2u0_hasAnnotation_C1825598> <https://research.tib.eu/covid-19/entity/36hwf2u0_hasAnnotation_C3541329> <https://research.tib.eu/covid-19/entity/36hwf2u0_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Bersanelli%2C_M.%3B_Giannarelli%2C_D.%3B_De_Giorgi%2C_U.%3B_Pignata%2C_S.%3B_Di_Maio%2C_M.%3B_Verzoni%2C_E.%3B_Clemente%2C_A.%3B_Guadalupi%2C_V.%3B_Signorelli%2C_D.%3B_Tiseo%2C_M.%3B_Giusti%2C_R.%3B_Filetti%2C_M.%3B_Di_Napoli%2C_M.%3B_Calvetti%2C_L.%3B_Cappetta%2C_A.%3B_Ermacora%2C_P.%3B_Zara%2C_D.%3B_Barbieri%2C_F.%3B_Baldessari%2C_C.%3B_Scotti%2C_V.%3B_Mazzoni%2C_F.%3B_Veccia%2C_A.%3B_Guglielmini%2C_P._F.%3B_Maruzzo%2C_M.%3B_Rossi%2C_E.%3B_Grossi%2C_F.%3B_Casadei%2C_C.%3B_Cortellini%2C_A.%3B_Verderame%2C_F.%3B_Montesarchio%2C_V.%3B_Rizzo%2C_M.%3B_Mencoboni%2C_M.%3B_Zustovich%2C_F.%3B_Fratino%2C_L.%3B_Cinieri%2C_S.%3B_Negrini%2C_G.%3B_Banzi%2C_M.%3B_Sorar%C3%B9%2C_M.%3B_Zucali%2C_P._A.%3B_Lacidogna%2C_G.%3B_Russo%2C_A.%3B_Battelli%2C_N.%3B_Fornarini%2C_G.%3B_Mucciarini%2C_C.%3B_Bracarda%2C_S.%3B_Bonetti%2C_A.%3B_Pezzuolo%2C_D.%3B_Longo%2C_L.%3B_Sartori%2C_D.%3B_Iannopollo%2C_M.%3B_Cavanna%2C_L.%3B_Meriggi%2C_F.%3B_Tassinari%2C_D.%3B_Corbo%2C_C.%3B_Gernone%2C_A.%3B_Prati%2C_V.%3B_Carnio%2C_S.%3B_Giordano%2C_P.%3B_Dicorato%2C_A._M.%3B_Verusio%2C_C.%3B_Atzori%2C_F.%3B_Carrozza%2C_F.%3B_Gori%2C_S.%3B_Castro%2C_A.%3B_Pilotto%2C_S.%3B_Vaccaro%2C_V.%3B_Garzoli%2C_E.%3B_Di_Costanzo%2C_F.%3B_Maiello%2C_E.%3B_Labianca%2C_R.%3B_Pinto%2C_C.%3B_Tognetto%2C_M.%3B_Buti%2C_S.>
?:journal	Therapeutic_Advances_in_Medical_Oncology
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/36hwf2u0_HAS_C3541329_ASSOCIATED_WITH_C0392171>
?:source	WHO
?:title	Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#913990
?:year	2020

Property

Value

?:abstract

Background: This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020 The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020 All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded Therefore, the study prospectively recorded all the COVID-19 ILI events Patients and methods: Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared the national emergency The prevalence of confirmed COVID-19 cases was detected as ILI episode with laboratory confirmation of SARS-CoV-2 Cases with clinical-radiological diagnosis of COVID-19 (COVID-like ILIs), were also reported Results: Out of 1257 enrolled patients, 955 matched the inclusion criteria for this unplanned analysis From 31 January to 30 April 2020, 66 patients had ILI: 9 of 955 cases were confirmed COVID-19 ILIs, with prevalence of 0 9% [95% confidence interval (CI): 0 3–2 4], a hospitalization rate of 100% and a mortality rate of 77 8% Including 5 COVID-like ILIs, the overall COVID-19 prevalence was 1 5% (95% CI: 0 5–3 1), with 100% hospitalization and 64% mortality The presence of elderly, males and comorbidities was significantly higher among patients vaccinated against influenza versus unvaccinated (p = 0 009, p < 0 0001, p < 0 0001) Overall COVID-19 prevalence was 1 2% for vaccinated (six of 482 cases, all confirmed) and 1 7% for unvaccinated (8 of 473, 3 confirmed COVID-19 and 5 COVID-like), p = 0 52 The difference remained non-significant, considering confirmed COVID-19 only (p = 0 33) Conclusion: COVID-19 has a meaningful clinical impact on the cancer-patient population receiving ICIs, with high prevalence, hospitalization and an alarming mortality rate among symptomatic cases Influenza vaccination does not protect from SARS-CoV-2 infection

is ?:annotates of

?:creator

<https://research.tib.eu/covid-19/entity/Bersanelli%2C_M.%3B_Giannarelli%2C_D.%3B_De_Giorgi%2C_U.%3B_Pignata%2C_S.%3B_Di_Maio%2C_M.%3B_Verzoni%2C_E.%3B_Clemente%2C_A.%3B_Guadalupi%2C_V.%3B_Signorelli%2C_D.%3B_Tiseo%2C_M.%3B_Giusti%2C_R.%3B_Filetti%2C_M.%3B_Di_Napoli%2C_M.%3B_Calvetti%2C_L.%3B_Cappetta%2C_A.%3B_Ermacora%2C_P.%3B_Zara%2C_D.%3B_Barbieri%2C_F.%3B_Baldessari%2C_C.%3B_Scotti%2C_V.%3B_Mazzoni%2C_F.%3B_Veccia%2C_A.%3B_Guglielmini%2C_P._F.%3B_Maruzzo%2C_M.%3B_Rossi%2C_E.%3B_Grossi%2C_F.%3B_Casadei%2C_C.%3B_Cortellini%2C_A.%3B_Verderame%2C_F.%3B_Montesarchio%2C_V.%3B_Rizzo%2C_M.%3B_Mencoboni%2C_M.%3B_Zustovich%2C_F.%3B_Fratino%2C_L.%3B_Cinieri%2C_S.%3B_Negrini%2C_G.%3B_Banzi%2C_M.%3B_Sorar%C3%B9%2C_M.%3B_Zucali%2C_P._A.%3B_Lacidogna%2C_G.%3B_Russo%2C_A.%3B_Battelli%2C_N.%3B_Fornarini%2C_G.%3B_Mucciarini%2C_C.%3B_Bracarda%2C_S.%3B_Bonetti%2C_A.%3B_Pezzuolo%2C_D.%3B_Longo%2C_L.%3B_Sartori%2C_D.%3B_Iannopollo%2C_M.%3B_Cavanna%2C_L.%3B_Meriggi%2C_F.%3B_Tassinari%2C_D.%3B_Corbo%2C_C.%3B_Gernone%2C_A.%3B_Prati%2C_V.%3B_Carnio%2C_S.%3B_Giordano%2C_P.%3B_Dicorato%2C_A._M.%3B_Verusio%2C_C.%3B_Atzori%2C_F.%3B_Carrozza%2C_F.%3B_Gori%2C_S.%3B_Castro%2C_A.%3B_Pilotto%2C_S.%3B_Vaccaro%2C_V.%3B_Garzoli%2C_E.%3B_Di_Costanzo%2C_F.%3B_Maiello%2C_E.%3B_Labianca%2C_R.%3B_Pinto%2C_C.%3B_Tognetto%2C_M.%3B_Buti%2C_S.>

?:journal

Therapeutic_Advances_in_Medical_Oncology

?:license

?:publication_isRelatedTo_Disease

<https://research.tib.eu/covid-19/entity/COVID-19>

is ?:relation_isRelatedTo_publication of

<https://research.tib.eu/covid-19/entity/36hwf2u0_HAS_C3541329_ASSOCIATED_WITH_C0392171>

?:source

?:title

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG

?:type